Abstract Metabolic reprogramming has garnered significant attention in recent years due to its therapeutic potential in cancer treatment
Community protocols describing subcutaneous injection at 1-2 mg/day are self-reported and undocumented in peer-reviewed literature
Type 2 diabetes mixed results: Theracurmin 180 mg/day (54 mg curcumin) for 6 months did not lower HbA1c versus placebo in 33 people with impaired glucose tolerance or type 2 diabetes [74]
De acordo com Guarnieri G, Bellinghieri G, Drueke TB, Horl WH et al, publicados em Am J Kidney Dis e Kidney Diseases, a suplementao pode restaurar os nveis adequados, melhorar o hematcrito, a hemoglobina e a albumina, alm de reduzir alteraes nos VLDL plasmticos6 e HDL-C
At standard doses of 1 mg or less daily, side effect rates were similar to placebo
10.1038/s41419-018-0801-9 43 ZhuL.ZhaoT.LiH.ZhaoH.WuL